John Miller's questions to Zymeworks Inc (ZYME) leadership • Q2 2025
Question
On behalf of John Miller from Evercore, an analyst asked about the key differentiating factors for ZW1528, questioning the relative contributions of its bispecific design versus its long half-life, and inquired about the planned dosing strategy for ZW251.
Answer
CSO Paul Moore explained that for ZW1528, both the bispecific targeting of IL-4/IL-33 and the half-life extension are integral design features for achieving superior efficacy. SVP of Clinical Development Sabeen Mekan stated that for ZW251, they can pursue a less conservative starting dose due to strong preclinical safety data and clinical experience with the same payload from the ZW191 program.